Mepolizumab intravenous (IV) vs placebo
FEV1 · people with asthma
1 finding from 1 review
- no estimate extracted2 studies · 690 participantsHigh
Findings
What do systematic reviews say?
32 questions · 33 findings · 2 reviews · Airways
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 5 · 15.2%Moderate 12 · 36.4%High 16 · 48.5%
Mepolizumab intravenous (IV) vs placebo
Serious adverse events · people with asthma
Mepolizumab intravenous (IV) leads to lower serious adverse events compared with placebo (high certainty).
1 finding from 1 review
- Risk ratio 0.59 [0.37, 0.94]3 studies · 751 participantsHigh
Mepolizumab intravenous (IV) vs placebo
Clinically significant adverse events leading to discontinuation · people with asthma
Mepolizumab intravenous (IV) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).
1 finding from 1 review
- Risk ratio 0.72 [0.18, 2.92]3 studies · 751 participantsHigh
Mepolizumab intravenous (IV) vs placebo
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Mepolizumab intravenous (IV) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
- Rate ratio 0.53 [0.44, 0.64]3 studies · 751 participantsHigh
Mepolizumab intravenous (IV) vs placebo
Rate of exacerbations requiring emergency department treatment or admission · people with asthma
Mepolizumab intravenous (IV) leads to lower rate of exacerbations requiring emergency department treatment or… compared with placebo (high certainty).
1 finding from 1 review
- Rate ratio 0.52 [0.31, 0.87]2 studies · 690 participantsHigh
Mepolizumab subcutaneous (SC) vs placebo
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Mepolizumab subcutaneous (SC) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
- Rate ratio 0.45 [0.36, 0.55]2 studies · 936 participantsHigh
Mepolizumab subcutaneous (SC) vs placebo
Rate of exacerbations requiring emergency department treatment or admission · people with asthma
Mepolizumab subcutaneous (SC) leads to lower rate of exacerbations requiring emergency department treatment or… compared with placebo (high certainty).
1 finding from 1 review
- Rate ratio 0.36 [0.2, 0.66]2 studies · 936 participantsHigh
Mepolizumab subcutaneous (SC) vs placebo
Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma
1 finding from 1 review
- no estimate extracted3 studies · 1231 participantsHigh
Mepolizumab subcutaneous (SC) vs placebo
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with asthma
1 finding from 1 review
- no estimate extracted3 studies · 1231 participantsHigh
Mepolizumab subcutaneous (SC) vs placebo
FEV1 · people with asthma
1 finding from 1 review
- no estimate extracted3 studies · 1231 participantsHigh
Mepolizumab subcutaneous (SC) vs placebo
Serious adverse events · people with asthma
Mepolizumab subcutaneous (SC) showed no clear difference in serious adverse events compared with placebo (high certainty).
1 finding from 1 review
- Risk ratio 0.68 [0.46, 1.01]3 studies · 1231 participantsHigh
Mepolizumab subcutaneous (SC) vs placebo
Clinically significant adverse events leading to discontinuation · people with asthma
Mepolizumab subcutaneous (SC) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).
1 finding from 1 review
- Risk ratio 0.6 [0.19, 1.85]3 studies · 1231 participantsHigh